VALANTINE HANNAH sold 53.7% of their position (8.67K shares) of BRIDGEBIO PHARMA, INC. on the open market
Open‑market sale worth $624.3K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/12/2026ACC: 0001470831-26-000260
-8.67K
Net shares
Net seller
$624.3K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
8.67K acquired · 17.34K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+8.67K
Price / share
$27.36
Trade value
$237.24K
% of position
116.2%
3/10/2026
7.46K→16.14K
Common Stock
Direct
Shares
−8.67K
Price / share
$72.00
Trade value
$624.31K
% of position
53.7%
3/10/2026
16.14K→7.46K
Total
Net shares
+0.00
Net value
-$387.07K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/10/2026 | M · Option Exercise | +8.67K | $27.36 | $237.24K | 116.2% | 7.46K | 16.14K |
| Common Stock Direct | 3/10/2026 | S · Sale | −8.67K | $72.00 | $624.31K | 53.7% | 16.14K | 7.46K |
| Total | +0.00 | -$387.07K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
8.67K shares
Shares
−8.67K
Strike price
27.36
Held after
17.34K
Exercisable
—
3/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock8.67K shares | 3/10/2026 | M · Option Exercise | −8.67K | 27.36 | — | 17.34K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned398.00
Total
398.00 indirect398.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 398.00 | Indirect |
| Total | 398.00 | 398.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported